Kelly Otto, M.S.

Kelly Otto has over 25 years of experience working in pharmaceutical and biologic development. As Senior Vice President Clinical Development Operations of Avalyn Pharma, Ms. Otto is an innovative thinker responsible for strategic direction of clinical development, clinical trial design, and successful delivery of company value.

Prior to joining Avalyn, Ms. Otto was Vice President Clinical Development Operations at Corus Pharma and was instrumental in the development of the inhaled antibiotic therapies Cayston® at Corus and TOBI® at PathoGenesis, both for the treatment of pseudomonal airway infections in patients with cystic fibrosis. Ms. Otto is an accomplished research professional with a Master of Science focused in Statistics from Florida State University.